Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism

[1]  M. Shuttleworth,et al.  Observational Study , 2019, Definitions.

[2]  M. Kurajoh,et al.  Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients With Normal Kidney Function by Lowering Serum Phosphorus , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  A. Boriano,et al.  Clinical Presentation of Primary Hyperparathyroidism in Older Adults , 2019, Journal of the Endocrine Society.

[4]  G. M. Díaz-Guerra,et al.  Trabecular Bone Score, Bone Mineral Density and Bone Markers in Patients with Primary Hyperparathyroidism 2 Years After Parathyroidectomy , 2019, Hormone and Metabolic Research.

[5]  F. García-Martín,et al.  Does renal function improve after parathyroidectomy in primary hyperparathyroidism? , 2019, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[6]  Sonsoles Guadalix,et al.  ¿Mejora la función renal tras la paratiroidectomía en el hiperparatirodismo primario? , 2019, Nefrología.

[7]  M. Emoto,et al.  Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency , 2018, Osteoporosis International.

[8]  M. Rubin,et al.  Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy , 2018, The Journal of clinical endocrinology and metabolism.

[9]  I. Chiodini,et al.  Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism , 2018, Journal of the American Geriatrics Society.

[10]  J. Bilezikian,et al.  Hyperparathyroidism , 2018, The Lancet.

[11]  M. Brandi,et al.  Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis , 2017, Osteoporosis International.

[12]  M. Emoto,et al.  Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis , 2017, Calcified Tissue International.

[13]  M. Rubin,et al.  Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism , 2017, Endocrine.

[14]  Ning Li,et al.  The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism , 2016, Annals of Internal Medicine.

[15]  M. Stechman,et al.  Does elective parathyroidectomy for primary hyperparathyroidism affect renal function? A prospective cohort study. , 2016, International journal of surgery.

[16]  P. Kostenuik,et al.  Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  F. Tassone,et al.  Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism. , 2015, The Journal of clinical endocrinology and metabolism.

[18]  R. Winzenrieth,et al.  Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS). , 2015, Bone.

[19]  C. Marcocci,et al.  Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. , 2014, The Journal of clinical endocrinology and metabolism.

[20]  R. Comi,et al.  Renal impairment as a surgical indication in primary hyperparathyroidism: do the data support this recommendation? , 2014, The Journal of clinical endocrinology and metabolism.

[21]  Heinrich Resch,et al.  Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  D. Borderie,et al.  Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[23]  S. Polyzos,et al.  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis , 2013, Clinical endocrinology.

[24]  I. Chiodini,et al.  Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. , 2013, European journal of endocrinology.

[25]  E. Romagnoli,et al.  "Trabecular Bone Score" (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. , 2013, Bone.

[26]  S. Cummings,et al.  Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  I. Bhan,et al.  Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  W. Leslie,et al.  Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: The manitoba study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  G. Martínez,et al.  The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy , 2011, Journal of Endocrinological Investigation.

[30]  S. Cummings,et al.  Effects of denosumab on fracture and bone mineral density by level of kidney function , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  P. Ituarte,et al.  Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism. , 2010, The Journal of clinical endocrinology and metabolism.

[32]  J. Bilezikian,et al.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.

[33]  B. Kinder,et al.  The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. , 2008, The Journal of clinical endocrinology and metabolism.

[34]  Hirofumi Makino,et al.  Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  L. Gianotti,et al.  A slight decrease in renal function further impairs bone mineral density in primary hyperparathyroidism. , 2006, The Journal of clinical endocrinology and metabolism.

[36]  S. Cummings,et al.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis , 1996 .

[37]  N. S. Riiodin.  Abbreviations. , 1927, Deleuze's Cinema Books.

[38]  R. Eastell,et al.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.

[39]  M. Perazella,et al.  Bisphosphonate nephrotoxicity. , 2008, Kidney international.

[40]  S. Cummings,et al.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  C. A. Fleming,et al.  The Acquisition of Data , 1969 .